Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 8 post-ruxolitinib window

Composite Biomarkers

Post-HSCT Monitoring - 28.1 months
Generated 2026-03-27 07:09 · Post-HSCT Patient
ADSI
Elevated
74.7/100
Autonomic Dysfunction | worsening (30-day trend)
Autonomic Dysfunction Severity Index. Higher = more dysfunction.
GVHD Score
Normal
21.7/100
Wearable Activity | worsening (30-day trend)
Composite from HRV, HR, sleep fragmentation, temperature. Ring-derived, not clinical diagnosis.
Recovery
Low
66.2/100
Trajectory Index | stable (30-day trend)
Overall recovery trajectory. Higher = better.
Pharma
Info
0.8Z
Ruxolitinib Response | stable (30-day trend)
Pharmacodynamic response to ruxolitinib. Z-score relative to pre-treatment baseline.
CV Risk
Elevated
63.4/100
Cardiovascular Composite | stable (30-day trend)
Cardiovascular risk proxy from resting HR, HRV, SpO2. Not equivalent to Framingham or SCORE2.
Allostatic
Normal
2.3/7
Load Score | stable (30-day trend)
Cumulative physiological stress burden. Scale 0-7.

Summary

Post-HSCT Patient | 28.1 months post-HSCT | Ruxolitinib from 2026-03-16

BiomarkerValueTrend
ADSI74.7/100worsening (30-day trend)
GVHD_SCORE21.7/100worsening (30-day trend)
RECOVERY_INDEX66.2/100stable (30-day trend)
CV_RISK63.4/100stable (30-day trend)
ALLOSTATIC_LOAD2.3/7stable (30-day trend)

Biomarker Dashboard

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.
Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.
Data: January 08 – March 23, 2026 · Post-intervention: 8 days (ruxolitinib, March 16)
Open source under MIT License · © 2026 The Educational Equality Institute · GitHub
Updated daily at 06:15 CET · Last generated: 2026-03-27 07:09
This project is not affiliated with, endorsed by, or sponsored by Oura Health Oy. Oura® is a registered trademark of Oura Health Oy.